Table 1:

Characteristics of the Study Population

Characteristic	Standard infliximab induction (n=132)	Accelerated infliximab induction (n=81)	p-value
Female (%)	45%	32%	0.05
Caucasian (%)	89%	84%	0.38
Mean Age at diagnosis, (SD) (in years)	33.0 (16.6)	31.0 (14.6)	0.36
Mean Disease duration, (SD) (in years)	4.2 (3.1)	4.6 (2.8)	0.67
UC extent pancolitis (%)	63%	76%	0.06
Current smoking (%)	3%	1%	0.39
Hospital site (%)			0.05
Massachusetts General Hospital	55%	42%
Indiana University Hospital	18%	32%
Johns Hopkins Hospital	27%	26%
Concomitant medications (%)
Aminosalicylates	58%	43%	0.03
Immunomodulators	24%	17%	0.23
Mean Laboratory results at hospital admission, (SD)
C-reactive protein (mg/dL)	29.6 (51.9)	35.5 (54.9)	0.50
ESR (mm/hr)	38 (24.9)	46 (26.2)	0.07
Albumin (g/dL)	3.2 (0.7)	3.1 (0.7)	0.49
Hemoglobin (g/dL)	11.5 (2.4)	11.0 (2.3)	0.20
Severe endoscopic inflammation (%)+	73%	84%	0.10

ESR – erythrocyte sedimentation rate

⁺Endoscopic evaluation (sigmoidoscopy/colonoscopy) performed in 177 patients